Rosetta Genomics Ltd
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LU… Read more
Rosetta Genomics Ltd (ROSGQ) - Total Assets
Latest total assets as of June 2017: $6.21 Million USD
Based on the latest financial reports, Rosetta Genomics Ltd (ROSGQ) holds total assets worth $6.21 Million USD as of June 2017.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rosetta Genomics Ltd - Total Assets Trend (2004–2016)
This chart illustrates how Rosetta Genomics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Rosetta Genomics Ltd - Asset Composition Analysis
Current Asset Composition (December 2016)
Rosetta Genomics Ltd's total assets of $6.21 Million consist of 79.5% current assets and 20.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.5% |
| Accounts Receivable | $2.92 Million | 24.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $625.00K | 5.2% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2016)
This chart illustrates how Rosetta Genomics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rosetta Genomics Ltd's current assets represent 79.5% of total assets in 2016, a decrease from 82.5% in 2004.
- Cash Position: Cash and equivalents constituted 51.5% of total assets in 2016, down from 72.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 24.4% of total assets.
Rosetta Genomics Ltd Competitors by Total Assets
Key competitors of Rosetta Genomics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Rosetta Genomics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Rosetta Genomics Ltd generates 0.77x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Rosetta Genomics Ltd is currently not profitable relative to its asset base.
Rosetta Genomics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 4.19 | 7.90 |
| Quick Ratio | 2.09 | 4.19 | 7.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.97 Million | $ 9.74 Million | $ 6.07 Million |
Rosetta Genomics Ltd - Advanced Valuation Insights
This section examines the relationship between Rosetta Genomics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.01 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -46.7% |
| Total Assets | $11.96 Million |
| Market Capitalization | $217.71 USD |
Valuation Analysis
Below Book Valuation: The market values Rosetta Genomics Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Rosetta Genomics Ltd's assets decreased by 46.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rosetta Genomics Ltd (2004–2016)
The table below shows the annual total assets of Rosetta Genomics Ltd from 2004 to 2016.
| Year | Total Assets | Change |
|---|---|---|
| 2016-12-31 | $11.96 Million | -46.66% |
| 2015-12-31 | $22.42 Million | +29.78% |
| 2014-12-31 | $17.28 Million | -33.24% |
| 2013-12-31 | $25.88 Million | -20.44% |
| 2012-12-31 | $32.53 Million | +1491.49% |
| 2011-12-31 | $2.04 Million | -61.38% |
| 2010-12-31 | $5.29 Million | -58.46% |
| 2009-12-31 | $12.74 Million | -37.13% |
| 2008-12-31 | $20.27 Million | -22.16% |
| 2007-12-31 | $26.04 Million | +96.62% |
| 2006-12-31 | $13.24 Million | +146.66% |
| 2005-12-31 | $5.37 Million | +158.00% |
| 2004-12-31 | $2.08 Million | -- |